BTRC抗体

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using BTRC mouse mAb against Ramos (1), MCF-7 (2), and K562 (3) cell lysate.    

  
  

•  

   

     Flow cytometric analysis of Hela cells using BTRC mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human esophageal cancer tissues using BTRC mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using BTRC mouse mAb with DAB staining.    

  
  

**Background of BTRC Antibody**

BTRC (Beta-Transducin Repeat Containing E3 Ubiquitin Protein Ligase), also known as β-TrCP, is a key component of the ubiquitin-proteasome system, responsible for substrate recognition and polyubiquitination, marking proteins for degradation. It functions as a substrate adaptor within the SKP1-CUL1-F-box (SCF) E3 ligase complex, targeting proteins involved in critical cellular processes such as cell cycle regulation, DNA damage response, and signal transduction (e.g., NF-κB, Wnt/β-catenin pathways). Dysregulation of BTRC is linked to cancer, inflammation, and neurodegenerative diseases.

BTRC antibodies are essential tools for studying its expression, localization, and interactions. They are widely used in techniques like Western blotting, immunoprecipitation, and immunofluorescence to investigate BTRC's role in disease mechanisms or therapeutic targeting. These antibodies often target specific regions, such as the F-box domain (critical for substrate binding) or WD40 repeats (involved in protein-protein interactions). Researchers also utilize BTRC antibodies to explore isoform-specific functions (e.g., β-TrCP1 vs. β-TrCP2) and its regulatory effects on oncoproteins (e.g., IκB, β-catenin). The development of high-specificity BTRC antibodies has advanced research into ubiquitination dynamics and potential inhibitors for cancer therapy.